Naproxen
ناپروکسن
🦴 Musculo-Skeletal SystemNSAID
Market / country: 🇺🇸 USA
Naprosyn (US)
🧮 Dose calculator
Mild to moderate pain · Regimen source: FDA Naproxen · 2.4
- • First dose 500 mg, then 250 mg every 6–8 h as needed; max 1,250 mg/day. FDA Naproxen · 2.4
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity; history of asthma, urticaria or allergic-type reaction after aspirin or other NSAIDs; in the setting of CABG surgery. FDA Naproxen · 4
- ⚠️ Boxed warning: risk of serious cardiovascular thrombotic events and GI bleeding, ulceration and perforation. FDA Naproxen · Boxed Warning
Formulations
- 250 mg tablet — tablet 🇺🇸 USA FDA Naproxen · 3
- 375 mg tablet — tablet 🇺🇸 USA FDA Naproxen · 3
- 500 mg tablet (scored) — tablet 🇺🇸 USA FDA Naproxen · 3
- 220 mg naproxen sodium caplet (OTC; = 200 mg naproxen) — tablet 🇺🇸 USA FDA Aleve caplets · Active ingredient
👥 Special populations
- 🤰 PregnancyDangerous / avoid
Label: can cause fetal harm. Dangerous in pregnancy. FDA Naproxen · 8.1
“… losure of ductus arteriosus), use during pregnancy (particularly starting at 30-weeks of gestation, or third trimester) should be avoided.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Naproxen · 8.2
“Risk Summary The naproxen anion has been found in the milk of lactating women at a concentration equivalent to approximately 1% of maximum naproxen concentration in plasma.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Naproxen · 8.4
“Safety and effectiveness in pediatric patients below the age of 2 years have not been established.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Naproxen · Boxed Warning
“Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events [ see Warnings and Precautions (5.2) ] .”
- ⚥ Females & males of reproductive potentialUse with caution
Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Naproxen · 8.3
“Infertility Females Based on the mechanism of action, the use of prostaglandin-mediated NSAIDs, including naproxen tablets may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women.”
🔗 Reference links
- FDA (approval record)ANDA074140
- DailyMed (FDA label)FDA Naproxen
- MedlinePlus (NIH)Naproxen
- WHO ATC/DDDM01AE02
- Darooyab (Iran)Naproxen
🇮🇷 Registered in Iran Darooyab · G-139/Naproxen
Dosage forms with Iranian generic codes, per Darooyab.
- 18457 · NAPROXEN 200MG SOFTGEL CAP · کپسول نرم ناپروکسن ۲۰۰ میلیگرم
- 00889 · NAPROXEN 250MG TAB · قرص ناپروکسن ۲۵۰ میلیگرم
- 17398 · NAPROXEN 375MG TAB · قرص ناپروکسن ۳۷۵ میلیگرم
- 02076 · NAPROXEN 500MG SUPP · شیاف ناپروکسن ۵۰۰ میلیگرم
- 01606 · NAPROXEN 500MG TAB · قرص ناپروکسن ۵۰۰ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Naproxen · 3FDA Aleve caplets · Active ingredientFDA Naproxen · 2.4FDA Naproxen · 2.1, Table 1FDA Naproxen · 2.2FDA Naproxen · 2.5FDA Naproxen · 2.3FDA Naproxen · 2FDA Aleve caplets · DirectionsFDA Naproxen · 4FDA Naproxen · Boxed WarningFDA Naproxen · 8.1FDA Naproxen · 8.2FDA Naproxen · 8.4FDA Naproxen · 8.3FDA Naproxen · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-139/Naproxen
- Clinical review⚠ Unverified